Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03532490 · ClinicalTrials.gov registry record · Phase 2
Trial of Roflumilast in Asthma Management (TRIM)
A Phase 2 study of Obesity and Asthma, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 7
- Study locations
NCT03532490: Completed Phase 2 study of Obesity and Asthma, sponsored by Johns Hopkins University.
NCT03532490 is a Phase 2 study of Obesity and Asthma that has completed, run by Johns Hopkins University. The registered enrollment target is 38 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03532490, a Phase 2 study of Obesity and Asthma, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 7
- Study locations
Study Summary
There are currently no treatments to specifically target asthma in obese adults. This pilot study is being conducted to investigate how effective roflumilast is in treating asthma in participants that have a higher BMI. Roflumilast can induce weight loss, which may lead to improved asthma control. The primary objective of TRIM is to perform a pilot placebo-controlled trial of roflumilast for the treatment of poorly controlled obese asthmatics.
Primary Outcome
The Asthma Control Test was designed to help participants describe their asthma and how it affects how they feel and what they are able to do. They choose a response based on their asthma within the last 4 weeks. Participants select how many times per week they experience different asthma symptoms and how often they had to use a rescue inhaler or nebulizer. There are 5 questions with 5 responses; 1 meaning their asthma is not well controlled or they had symptoms more frequently, through 5 meanin
Interventions
- DRUG Placebo oral capsule
- DRUG Roflumilast 500 Mcg Oral Tablet
Study Locations (7)
Illinois
- University of Illinois at Chicago, Breathe Chicago Center - Chicago
- Northwestern University Feinberg School of Medicine - Chicago
Alabama
- University of Alabama Lung Health Center - Birmingham
Arizona
- University of Arizona - Tucson
New York
- Mount Sinai Icahn School of Medicine - New York
North Carolina
- Duke University - Durham
Vermont
- University of Vermont - Colchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-08-03 |
| Est. Completion | 2021-07-30 |
| Phase | Phase 2 |
What the finished NCT03532490 record still lists
NCT03532490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03532490 lists 7 locations in 6 states (Illinois, Alabama, Arizona).
Frequently Asked Questions
What is clinical trial NCT03532490 about?
NCT03532490 is a clinical study titled "Trial of Roflumilast in Asthma Management (TRIM)". There are currently no treatments to specifically target asthma in obese adults. This pilot study is being conducted to investigate how effective roflumilast is in treating asthma in participants that have a higher BMI. Roflumilast can induce weight loss, which may lead to improved asthma control. ...
What is the current status of trial NCT03532490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2018-08-03. Estimated completion is 2021-07-30.
What conditions does trial NCT03532490 study?
This clinical trial studies the following conditions: Obesity, Asthma.
What interventions are being tested in trial NCT03532490?
The interventions under investigation include: Placebo oral capsule (DRUG), Roflumilast 500 Mcg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03532490?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03532490 being conducted?
This trial has 7 study locations across Alabama, Arizona, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03532490's enrollment target sits among peer trials
38 811th of 1053 higher than 239 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI